Osteopontin stimulates invasion of NCI-h295 cells but is not associated with survival in adrenocortical carcinoma

Journal of Pathology

Volumn 218, Issue 2, 2009, Pages 232-240

  Weismann, Dirk ^a   Briese, Juliane ^b,c,d,e   Niemann, Joscha ^f   Grüneberger, Matthias ^a   Adam, Patrick ^g   Hahner, Stefanie ^a   Johanssen, Sarah ^a   Liu, Wei ^b,c   Ezzat, Shereen ^h   Saeger, Wolfgang ⁱ   Bamberger, Ana Maria ^f   Fassnacht, Martin ^a   Schulte, Heinrich M ^j   Asa, Sylvia L ^b,c   Allolio, Bruno ^a   Bamberger, Christoph M ^f  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e UNIVERSITY OF GREIFSWALD   (Germany)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g UNIVERSITY OF WÜRZBURG   (Germany)

^h MOUNT SINAI HOSPITAL   (Canada)

ⁱ Institute for Pathology   (Germany)

^j ENDOKRINOLOGIKUM HAMBURG   (Germany)

more..

Author keywords

Adrenocortical cancer; Invasion; OPN; Osteopontin; Proliferation; Tissue microarray

Indexed keywords

OSTEOPONTIN; RECEPTOR ANTIBODY; VITRONECTIN RECEPTOR;

ADRENAL CORTEX ADENOMA; ADRENAL CORTEX CARCINOMA; ADRENAL CORTEX CELL; ADULT; ARTICLE; BENIGN TUMOR; CANCER INVASION; CANCER SURVIVAL; CELL INVASION; CONTROLLED STUDY; CUSHING SYNDROME; FEMALE; FOLLOW UP; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NODULAR HYPERPLASIA; PRIMARY TUMOR; PRIORITY JOURNAL; SURVIVAL TIME;

ADENOMA; ADRENAL CORTEX NEOPLASMS; ADRENAL GLANDS; ADRENOCORTICAL CARCINOMA; BLOTTING, WESTERN; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; INTEGRIN ALPHAVBETA3; KAPLAN-MEIERS ESTIMATE; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOPONTIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STATISTICS, NONPARAMETRIC; TRANSFECTION;

EID: 66849087625     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2528     Document Type: Article

References (54)

1. Allolio B, Hahner S, Weismann D, Fassnacht M. Management of adrenocortical carcinoma. Clin Endocrinol (Oxford) 2004;60:273-287. (Pubitemid 38297116)
2. Libe R, Fratticci A, Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer 2007;14:13-28. (Pubitemid 47521719)
3. Assie G, Antoni G, Tissier F, Caillou B, Abiven G, Gicquel C, et al. Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 2007;92:148-154. (Pubitemid 46067523)
4. Allolio B, Fassnacht M. Clinical review: adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 2006;91:2027-2037. (Pubitemid 43854976)
5. Dackiw AP, Lee JE, Gagel RF, Evans DB. Adrenal cortical carcinoma. World J Surg 2001;25:914-926. (Pubitemid 32666394)
6. National Cancer Institute. Third national cancer survey: incidental data. In DHEW Publication No (NIH) 75-787. 1975 NCI Monograph, pp. 41. National Cancer Institute, Bethesda.
7. Wajchenberg BL, Albergaria Pereira MA, Medonca BB, Latronico AC, Campos Carneiro P, Alves VA, et al. Adrenocortical carcinoma: clinical and laboratory observations. Cancer 2000;88:711-736. (Pubitemid 30091090)
8. Koch CA, Pacak K, Chrousos GP. The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors. J Clin Endocrinol Metab 2002;87:5367-5384.
9. Kirschner LS. Signaling pathways in adrenocortical cancer. Ann N Y Acad Sci 2002;968:222-239. (Pubitemid 34721883)
10. Kjellman M, Larsson C, Backdahl M. Genetic background of adrenocortical tumor development. World J Surg 2001;25:948-956. (Pubitemid 32666398)
11. Reincke M. Mutations in adrenocortical tumors. Horm Metab Res 1998;30:447-455. (Pubitemid 28308026)
12. Giordano TJ, Thomas DG, Kuick R, Lizyness M, Misek DE, Smith AL, et al. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol 2003;162:521-531. (Pubitemid 36267859)
13. Tuck AB, Chambers AF. The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia 2001;6:419-429. (Pubitemid 39600499)
14. Tuck AB, O'Malley FP, Singhal H, Tonkin KS, Harris JF, Bautista D, et al. Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch Pathol Lab Med 1997;121:578-584. (Pubitemid 27259939)
15. Chambers AF, Wilson SM, Kerkvliet N, O'Malley FP, Harris JF, Casson AG. Osteopontin expression in lung cancer. Lung Cancer 1996;15:311-323. (Pubitemid 26399511)
16. Thalmann GN, Sikes RA, Devoll RE, Kiefer JA, Markwalder R, Klima I, et al. Osteopontin: possible role in prostate cancer progression. Clin Cancer Res 1999;5:2271-2277. (Pubitemid 29399287)
17. Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 2002;94:513-521. (Pubitemid 34411290)
18. Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. J Am Med Assoc 2002;287:1671-1679. (Pubitemid 34289219)
19. Ue T, Yokozaki H, Kitadai Y, Yamamoto S, Yasui W, Ishikawa T, et al. Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer 1998;79:127-132. (Pubitemid 28201682)
20. Furger KA, Menon RK, Tuck AB, Bramwell VH, Chambers AF. The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 2001;1:621-632. (Pubitemid 33772040)
21. Oates AJ, Barraclough R, Rudland PS. The role of osteopontin in tumorigenesis and metastasis. Invasion Metastasis 1997;17:1-15. (Pubitemid 27525063)
22. Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 2004;10:184-190. (Pubitemid 38114178)
23. Barraclough R, Chen HJ, Davies BR, Davies MP, Ke Y, Lloyd BH, et al. Use of DNA transfer in the induction of metastasis in experimental mammary systems. Biochem Soc Symp 1998;63:273-294. (Pubitemid 128669570)
24. Wu Y, Denhardt DT, Rittling SR. Osteopontin is required for full expression of the transformed phenotype by the ras oncogene. Br J Cancer 2000;83:156-163. (Pubitemid 30411711)
25. Oates AJ, Barraclough R, Rudland PS. The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. Oncogene 1996;13:97-104. (Pubitemid 26248549)
26. Denhardt DT, Chambers AF. Overcoming obstacles to metastasis - defenses against host defenses: osteopontin (OPN) as a shield against attack by cytotoxic host cells. J Cell Biochem 1994;56:48-51. (Pubitemid 24288109)
27. Briese J, Oberndorfer M, Patschenik C, Schulte HM, Makrigiannakis A, Loning T, et al. Osteopontin is colocalized with the adhesion molecule CEACAM1 in the extravillous trophoblast of the human placenta and enhances invasion of CEACAM1-expressing placental cells. J Clin Endocrinol Metab 2005;90:5407-5413. (Pubitemid 41262309)
28. Briese J, Oberndorfer M, Schulte HM, Loning T, Bamberger AM. Osteopontin expression in gestational trophoblastic diseases: correlation with expression of the adhesion molecule, CEACAM1. Int J Gynecol Pathol 2005;24:271-276. (Pubitemid 40885082)
29. Yue TL, McKenna PJ, Ohlstein EH, Farach-Carson MC, Butler WT, Johanson K, et al. Osteopontin-stimulated vascular smooth muscle cell migration is mediated by beta 3 integrin. Exp Cell Res 1994;214:459-464. (Pubitemid 24310803)
30. Allan AL, George R, Vantyghem SA, Lee MW, Hodgson NC, Engel CJ, et al. Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer. Am J Pathol 2006;169:233-246; DOI 169/1/233 [pii].
31. Mi Z, Guo H, Wai PY, Gao C, Kuo PC. Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells. Carcinogenesis 2006;27:1134-1145; DOI bgi352 [pii] 10.1093/carcin/bgi352 [doi]. (Pubitemid 43985428)
32. Gazdar AF, Oie HK, Shackleton CH, Chen TR, Triche TJ, Myers CE, et al. Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis. Cancer Res 1990;50:5488-5496. (Pubitemid 20303009)
33. Fassnacht M, Franke A, Dettling A, Hahner S, Zink M, Wudy S, et al. Clodronate inhibits adrenocortical cell proliferation and P450c21 activity. J Endocrinol 2002;174:509-516.
34. Brummer J, Ebrahimnejad A, Flayeh R, Schumacher U, Loning T, Bamberger AM, et al. Cis interaction of the cell adhesion molecule CEACAM1 with integrin beta(3). Am J Pathol 2001;159:537-546. (Pubitemid 32751084)
35. Gell JS, Oh J, Rainey WE, Carr BR. Effect of estradiol on DHEAS production in the human adrenocortical cell line, H295R. J Soc Gynecol Invest 1998;5:144-148. (Pubitemid 28248540)
36. Rainey WE, Bird IM, Sawetawan C, Hanley NA, McCarthy JL, McGee EA, et al. Regulation of human adrenal carcinoma cell (NCI-H295) production of C19 steroids. J Clin Endocrinol Metab 1993;77:731-737. (Pubitemid 23298657)
37. R, Team RDC. R: A Language and Environment for Statistical Computing (R version 2.5.0 (2007-04-23) edn). R Foundation for Statistical Computing: Vienna, Austria. ISBN 3-90051-07-10, URL: http://www.R-project.org.
38. Ribeiro-Silva A, Oliveira da Costa JP. Osteopontin expression according to molecular profile of invasive breast cancer: a clinicopathological and immunohistochemical study. Int J Biol Markers 2008;23:154-160.
39. Castellano G, Malaponte G, Mazzarino MC, Figini M, Marchese F, Gangemi P, et al. Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression. Clin Cancer Res 2008;14:7470-7480.
40. Sun BS, Dong QZ, Ye QH, Sun HJ, Jia HL, Zhu XQ, et al. Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Hepatology 2008;48:1834-1842.
41. Fong YC, Liu SC, Huang CY, Li TM, Hsu SF, Kao ST, et al. Osteopontin increases lung cancer cells migration via activation of the alphavbeta3 integrin/FAK/Akt and NF-kappaB-dependent pathway. Lung Cancer 2008;in press. DOI:10.1016/j.lungcan.2008.09.003.
42. Rangaswami H, Bulbule A, Kundu GC. Nuclear factor inducing kinase: a key regulator in osteopontin-induced MAPK/IkappaB kinase dependent NF-kappaB-mediated promatrix metalloproteinase-9 activation. Glycoconj J 2006;23:221-232; DOI 10.1007/s10719-006-7927-7931 [doi]. (Pubitemid 43725201)
43. Song G, Ming Y, Mao Y, Bao S, Ouyang G. Osteopontin prevents curcumin-induced apoptosis and promotes survival through Akt activation via alphavbeta3 integrins in human gastric cancer cells. Exp Biol Med (Maywood) 2008;233:1537-1545; DOI 0805-RM-164 [pii]10.3181/0805-RM-164 [doi].
44. Angelucci A, Festuccia C, Gravina GL, Muzi P, Bonghi L, Vicentini C, et al. Osteopontin enhances the cell proliferation induced by the epidermal growth factor in human prostate cancer cells. Prostate 2004;59:157-166. (Pubitemid 38481227)
45. Gao C, Guo H, Downey L, Marroquin C, Wei J, Kuo PC. Osteopontin-dependent CD44v6 expression and cell adhesion in HepG2 cells. Carcinogenesis 2003;24:1871-1878. (Pubitemid 38016163)
46. Kasugai S, Todescan R Jr, Nagata T, Yao KL, Butler WT, Sodek J. Expression of bone matrix proteins associated with mineralized tissue formation by adult rat bone marrow cells in vitro: inductive effects of dexamethasone on the osteoblastic phenotype. J Cell Physiol 1991;147:111-120. (Pubitemid 21910089)
47. Prince CW, Butler WT. 1,25-Dihydroxyvitamin D3 regulates the biosynthesis of osteopontin, a bone-derived cell attachment protein, in clonal osteoblast-like osteosarcoma cells. Coll Relat Res 1987;7:305-313. (Pubitemid 17128256)
48. Feltus FA, Kovacs WJ, Nicholson W, Silva CM, Nagdas SK, Ducharme NA, et al. Epidermal growth factor increases cortisol production and type II 3 beta-hydroxysteroid dehydrogenase/Delta(5)-Delta(4)-isomerase expression in human adrenocortical carcinoma cells: evidence for a Stat5-dependent mechanism. Endocrinology 2003;144:1847-1853. (Pubitemid 36543323)
49. Parmar J, Key RE, Rainey WE. Development of an adrenocorticotropin- responsive human adrenocortical carcinoma cell line. J Clin Endocrinol Metab 2008;93:4542-4546. (Pubitemid 352789558)
50. Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Br J Cancer 2004;90:1877-1881. (Pubitemid 38746324)
51. Medico E, Gentile A, Lo Celso C, Williams TA, Gambarotta G, Trusolino L, et al. Osteopontin is an autocrine mediator of hepatocyte growth factor-induced invasive growth. Cancer Res 2001;61:5861-5868. (Pubitemid 32769106)
52. Chackalaparampil I, Peri A, Nemir M, McKee MD, Lin PH, Mukherjee BB, et al. Cells in vivo and in vitro from osteopetrotic mice homozygous for c-src disruption show suppression of synthesis of osteopontin, a multifunctional extracellular matrix protein. Oncogene 1996;12:1457-1467. (Pubitemid 26132033)
53. Su L, Mukherjee AB, Mukherjee BB. Expression of antisense osteopontin RNA inhibits tumor promoter-induced neoplastic transformation of mouse JB6 epidermal cells. Oncogene 1995;10:2163-2169.
54. Wai PY, Guo L, Gao C, Mi Z, Guo H, Kuo PC. Osteopontin inhibits macrophage nitric oxide synthesis to enhance tumor proliferation. Surgery 2006;140:132-140. (Pubitemid 44176055)